Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 175-182

  Chow, Vincent ^a,b,c   Reddel, Caroline ^a,b,c   Pennings, Gabrielle ^a,b,c   Scott, Elizabeth ^c   Pasqualon, Tundra ^d   Ng, Austin C C ^b,c   Yeoh, Thomas ^b   Curnow, Jennifer ^a,b,c   Kritharides, Leonard ^a,b,c  

^a ANZAC RESEARCH INSTITUTE   (Australia)

^b ANZAC Research Institute   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Department of Psychiatry   (Australia)

Author keywords

Blood coagulation test; Coagulation; Fibrinolysis; Schizophrenia; Thrombosis

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; C REACTIVE PROTEIN; CITALOPRAM; CLOZAPINE; D DIMER; ESCITALOPRAM; FIBRINOGEN; FLUOXETINE; LAMOTRIGINE; LITHIUM SALT; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUETIAPINE; RISPERIDONE; SERTRALINE; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VALPROIC ACID; VENLAFAXINE; ZUCLOPENTHIXOL; FIBRIN;

ADJUVANT THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEEP VEIN THROMBOSIS; DRUG OVERDOSE; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERCOAGULABILITY; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL COAGULATION POTENTIAL; OVERALL FIBRINOLYTIC POTENTIAL; OVERALL HEMOSTATIC POTENTIAL; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMA; SPECTROPHOTOMETRY; THROMBOPHILIA;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD COAGULATION; FEMALE; FIBRIN; HUMANS; MALE; PLASMA; SCHIZOPHRENIA; SPECTROPHOTOMETRY; THROMBOPHILIA; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84923227235     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.12.042     Document Type: Article

References (77)

1. Agarwal V., Phung O.J., Tongbram V., Bhardwaj A., Coleman C.I. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int. J. Clin. Pract. 2010, 64(10):1375-1383.
2. Ageno W., Squizzato A., Garcia D., Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin. Thromb. Hemost. 2006, 36:772-779. (32(7), 651-658).
3. Ageno W., Becattini C., Brighton T., Selby R., Kamphuisen P.W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008, 117(1):93-102.
4. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286(1):64-70.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, (Washington, DC). 4th edition.
6. Anderson F.A., Spencer F.A. Risk factors for venous thromboembolism. Circulation 2003, 107(23 Suppl. 1):I9-I16.
7. Authors/Task Force, Konstantinides M., Torbicki S.V., Agnelli A., Danchin G., Fitzmaurice N., Galie D., Gibbs N., Huisman J.S., Humbert M.V., Kucher M., Lang N., Lankeit I., Lekakis M., Maack J., Mayer C., Meneveau E., Perrier N., Pruszczyk A., Rasmussen P., Schindler L.H., Svitil T.H., Vonk Noordegraaf P., Zamorano A., Zompatori J.L., Authors/Task Force 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur. Heart J. 2014, 35(43):3033-3069.
8. Axelsson S., Hagg S., Eriksson A.C., Lindahl T.L., Whiss P.A. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin. Exp. Pharmacol. Physiol. 2007, 34(8):775-780. (34(8), 775-780).
9. Baglin T., Gray E., Greaves M., Hunt B.J., Keeling D., Machin S., Mackie I., Makris M., Nokes T., Perry D., Tait R.C., Walker I., Watson H. Clinical guidelines for testing for heritable thrombophilia. Br. J. Haematol. 2010, 149(2):209-220.
10. Bank I., van de Poel M.H., Coppens M., Hamulyak K., Prins M.H., van der Meer J., Veeger N.J., Buller H.R., Middeldorp S. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study. Thromb. Haemost. 2007, 98(5):1040-1044.
11. Boullin D.J., Know J.M., Peters J.R., Orr M.W., Gelder M.G., Grahame-Smith D.G. Platelet aggregation and chlorpromazine therapy. Br. J. Clin. Pharmacol. 1978, 6(6):538-540.
12. Braekkan S.K., Borch K.H., Mathiesen E.B., Njolstad I., Hansen J.B. HDL-cholesterol and future risk of venous thromboembolism: the Tromso Study. J. Thromb. Haemost. 2009, 7(8):1428-1430.
13. Bucciarelli P., Passamonti S.M., Biguzzi E., Gianniello F., Franchi F., Mannucci P.M., Martinelli I. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J. Thromb. Haemost. 2012, 10(9):1783-1791.
14. Carrizo E., Fernandez V., Quintero J., Connell L., Rodriguez Z., Mosquera M., Acosta A., Baptista T. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr. Res. 2008, 103(1-3):83-93.
15. Cellai A.P., Lami D., Antonucci E., Fiorillo C., Becatti M., Olimpieri B., Bani D., Grifoni E., Cenci C., Marcucci R., Mannini L., Poli D., Abbate R., Prisco D. Fibrinolytic inhibitors and fibrin characteristics determine a hypofibrinolytic state in patients with pulmonary embolism. Thromb. Haemost. 2013, 109(3):565-567.
16. Cesari M., Pahor M., Incalzi R.A. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc. Ther. 2010, 28(5):e72-e91.
17. Chamberlain A.M., Folsom A.R., Heckbert S.R., Rosamond W.D., Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood 2008, 112(7):2675-2680.
18. Curnow J.L., Morel-Kopp M.C., Roddie C., Aboud M., Ward C.M. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J. Thromb. Haemost. 2007, 5(3):528-534.
19. Davis S., Kern H.B., Asokan R. Antiphospholipid antibodies associated with clozapine treatment. Am. J. Hematol. 1994, 46(2):166-167. (46(2), 166-167).
20. Edelman J.J., Reddel C.J., Kritharides L., Bannon P.G., Fraser J.F., Curnow J.L., Vallely M.P. Natural history of hypercoagulability in patients undergoing coronary revascularization and effect of preoperative myocardial infarction. J. Thorac. Cardiovasc. Surg. 2013, 148(2):536-543.
21. Eichinger S., Pecheniuk N.M., Hron G., Deguchi H., Schemper M., Kyrle P.A., Griffin J.H. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007, 115(12):1609-1614.
22. Everett B.M., Glynn R.J., Buring J.E., Ridker P.M. Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J. Thromb. Haemost. 2009, 7(4):588-596.
23. Fitzsimons J., Berk M., Lambert T., Bourin M., Dodd S. A review of clozapine safety. Expert Opin. Drug Saf. 2005, 4(4):731-744.
24. Furie B., Furie B.C. Mechanisms of thrombus formation. N. Engl. J. Med. 2008, 359(9):938-949.
25. Glynn R.J., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Ridker P.M. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009, 360(18):1851-1861.
26. Griffin J.H., Kojima K., Banka C.L., Curtiss L.K., Fernandez J.A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 1999, 103(2):219-227.
27. Guimaraes A.H., de Bruijne E.L., Lisman T., Dippel D.W., Deckers J.W., Poldermans D., Rijken D.C., Leebeek F.W. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br. J. Haematol. 2009, 145(1):115-120.
28. Hagg S., Jonsson A.K., Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin. Drug Saf. 2009, 8(5):537-547.
29. He S., Bremme K., Blomback M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb. Res. 1999, 96(2):145-156.
30. He S., Antovic A., Blomback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb. Res. 2001, 103(5):355-361.
31. Hu Q., Zhang C., Zhu S. Fatal multisystem venous thrombosis associated with clozapine. J. Clin. Psychopharmacol. 2013, 33(2):256-258.
32. Iwata Y., Suzuki K., Nakamura K., Matsuzaki H., Sekine Y., Tsuchiya K.J., Sugihara G., Kawai M., Minabe Y., Takei N., Mori N. Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia. Schizophr. Res. 2007, 89(1-3):154-160.
33. Jenkins P.V., Rawley O., Smith O.P., O'Donnell J.S. Elevated factor VIII levels and risk of venous thrombosis. Br. J. Haematol. 2012, 157(6):653-663.
34. Jenkins P.V., Rawley O., Smith O.P., O'Donnell J.S. Elevated factor VIII levels and risk of venous thrombosis. Br. J. Haematol. 2012, 157(6):653-663. (157(6), 653-663).
35. Jennings I., Kitchen S., Woods T.A., Preston F.E. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin. Thromb. Hemost. 2005, 31(1):66-72.
36. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995, 345(8943):152-155.
37. Koster T., Rosendaal F.R., Briet E., van der Meer F.J., Colly L.P., Trienekens P.H., Poort S.R., Reitsma P.H., Vandenbroucke J.P. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995, 85(10):2756-2761.
38. Li L., Sun T., Zhang P., Tian J., Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database Syst. Rev. 2011, 12:(CD008203).
39. Lisman T., de Groot P.G., Meijers J.C., Rosendaal F.R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005, 105(3):1102-1105.
40. Machin S.J. Pros and cons of thrombophilia testing: cons. J. Thromb. Haemost. 2003, 1(3):412-413.
41. Mahmoodi B.K., Brouwer J.L., Ten Kate M.K., Lijfering W.M., Veeger N.J., Mulder A.B., Kluin-Nelemans H.C., Van Der Meer J. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J. Thromb. Haemost. 2010, 8(6):1193-1200.
42. Masopust J., Maly R., Andrys C., Valis M., Bazant J., Hosak L. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011, 11:2.
43. Meltzer M.E., Lisman T., Doggen C.J., de Groot P.G., Rosendaal F.R. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med. 2008, 5(5):e97.
44. Meltzer M.E., Doggen C.J., de Groot P.G., Rosendaal F.R., Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br. J. Haematol. 2009, 145(1):121-127.
45. Meltzer M.E., Lisman T., de Groot P.G., Meijers J.C., le Cessie S., Doggen C.J., Rosendaal F.R. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010, 116(1):113-121.
46. Middeldorp S. Evidence-based approach to thrombophilia testing. J. Thromb. Thrombolysis 2011, 31(3):275-281.
47. Middeldorp S. Is thrombophilia testing useful?. Hematol. Am. Soc. Hematol. Educ. Prog. 2011, 2011:150-155.
48. Middeldorp S., van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients?. Br. J. Haematol. 2008, 143(3):321-335.
49. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98(11):1352-1364.
50. Ng A.C., Chung T., Yong A.S., Wong H.S., Chow V., Celermajer D.S., Kritharides L. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ. Cardiovasc. Qual. Outcomes 2011, 4(1):122-128.
51. Nishino M., Hoshida S., Kato H., Egami Y., Shutta R., Yamaguchi H., Tanaka K., Tanouchi J., Hori M., Yamada Y. Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ. J. 2008, 75(6):1472-1475. (72(2), 232-237).
52. Pai M., Evans N.S., Shah S.J., Green D., Cook D., Crowther M.A. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb. Res. 2011, 122(1):21-25. (128(5), 422-430).
53. Parker C., Coupland C., Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010, 341:c4245.
54. Parkin L., Skegg D.C., Herbison G.P., Paul C. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol. Drug Saf. 2003, 12(8):647-652. (12(8), 647-652).
55. Perez A., Bartholomew J.R. Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. Cleve. Clin. J. Med. 2010, 74(3):199-202. (77(3), 191-194).
56. Reddel C.J., Curnow J.L., Voitl J., Rosenov A., Pennings G.J., Morel-Kopp M.-C., Brieger D.B. Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay. Thromb. Res. 2013, 122(1):21-25. (131(5), 457-462).
57. Reitter-Pfoertner S., Waldhoer T., Mayerhofer M., Eigenbauer E., Ay C., Mannhalter C., Kyrle P.A., Pabinger I. The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. Thromb. Haemost. 2013, 109(1):79-84.
58. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Muller M.R., Husslein P., Kashanipour A., Minar E., Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2002, 22(7):1194-1199.
59. Roche-Bayard P., Rossi R., Mann J.M., Cordier J.F., Delahaye J.P. Left pulmonary artery thrombosis in chlorpromazine-induced lupus. Chest 1990, 98(6):1545.
60. Rodriguez A.L., Wojcik B.M., Wrobleski S.K., Myers D.D., Wakefield T.W., Diaz J.A. Statins, inflammation and deep vein thrombosis: a systematic review. J. Thromb. Thrombolysis 2012, 33(4):371-382. (33(4), 371-382).
61. Rogers M.A., Levine D.A., Blumberg N., Flanders S.A., Chopra V., Langa K.M. Triggers of hospitalization for venous thromboembolism. Circulation 2012, 125(17):2092-2099.
62. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279(20):1643-1650.
63. Squizzato A., Galli M., Romualdi E., Dentali F., Kamphuisen P.W., Guasti L., Venco A., Ageno W. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur. Heart J. 2010, 31(10):1248-1256.
64. Stein P.D., Kayali F., Olson R.E. Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am. J. Cardiol. 2004, 93(9):1197-1199.
65. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galie N., Pruszczyk P., Bengel F., Brady A.J., Ferreira D., Janssens U., Klepetko W., Mayer E., Remy-Jardin M., Bassand J.P., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Andreotti F., Ascherman M., Athanassopoulos G., De Sutter J., Fitzmaurice D., Forster T., Heras M., Jondeau G., Kjeldsen K., Knuuti J., Lang I., Lenzen M., Lopez-Sendon J., Nihoyannopoulos P., Perez Isla L., Schwehr U., Torraca L., Vachiery J.L. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008, 29(18):2276-2315.
66. Undas A., Brozek J., Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin. Lab. 2002, 48(5-6):287-296. (48(5-6), 287-296).
67. Undas A., Brummel-Ziedins K.E., Mann K.G. Statins and blood coagulation. Arterioscler. Thromb. Vasc. Biol. 2005, 23(10):1881-1888. (25(2), 287-294).
68. Van De Craen B., Declerck P.J., Gils A. The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb. Res. 2012, 122(1):21-25. (130(4), 576-585).
69. Varia I., Krishnan R.R., Davidson J. Deep-vein thrombosis with antipsychotic drugs. Psychosomatics 1983, 24(12):1097-1098.
70. Vedin J., Antovic A., Ericsson A., Vaage J. Hemostasis in off-pump compared to on-pump coronary artery bypass grafting: a prospective, randomized study. Ann. Thorac. Surg. 2005, 80(2):586-593.
71. Waldman A., Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003, 63(2):139-152.
72. Walker A.M., Lanza L.L., Arellano F., Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 1997, 8(6):671-677.
73. Walsh M.T., Ryan M., Hillmann A., Condren R., Kenny D., Dinan T., Thakore J.H. Elevated expression of integrin alpha(IIb) beta(IIIa) in drug-naive, first-episode schizophrenic patients. Biol. Psychiatry 2002, 52(9):874-879. (52(9), 874-879).
74. Wang Y., Wang P., Li H. Correlation study of pulmonary embolism and high-density lipoprotein cholesterol. Clin. Cardiol. 2010, 33(2):72-76.
75. Whiteman T., Hassouna H.I. Hypercoagulable states. Hematol. Oncol. Clin. North Am. 2000, 14(2):355-377. (viii).
76. Yukizawa Y., Inaba Y., Watanabe S., Yajima S., Kobayashi N., Ishida T., Iwamoto N., Choe H., Saito T. Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty. Acta Orthop. 2012, 83(1):14-21. (83(1), 14-21).
77. Zornberg G.L., Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000, 356(9237):1219-1223.